IN8bio (MUN:6JH) - Aandelenkoers, Nieuws & Analyse

6JH Overzicht aandelen

A clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of solid and liquid tumors.

Over het bedrijf

6JH fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Risicoanalyse

De winst is de afgelopen 5 jaar met 47% per jaar gedaald

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

Aandelen zijn zeer illiquide

Heeft geen betekenisvolle marktkapitalisatie ( €37M )

+ 1 meer risico

IN8bio, Inc. Concurrenten

Medigene

XTRA:MDG1

€25.0m

2invest

XTRA:2INV

€59.8m

4SC

DB:VSC

€61.5m

Heidelberg Pharma

XTRA:HPHA

€111.9m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor IN8bio
Historische aandelenkoersen
Huidige aandelenkoers	US$2.78
52 Week Hoogtepunt	US$6.13
52 Week Laag	US$1.96
Bèta	0
11 maand verandering	0%
3 maanden verandering	-7.33%
1 Jaar Verandering	-50.24%
33 jaar verandering	n/a
5 jaar verandering	n/a
Verandering sinds IPO	-66.83%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	6JH	DE Biotechs	DE Markt
7D	0%	0.5%	-1.4%
1Y	-50.2%	-16.2%	11.8%

Rendement versus industrie: 6JH presteerde slechter dan de German Biotechs -sector, die het afgelopen jaar een rendement van -16.2 % opleverde.

Rendement versus markt: 6JH presteerde slechter dan German Market, dat het afgelopen jaar een rendement van 11.8 % opleverde.

Prijsvolatiliteit

Is 6JH's price volatile compared to industry and market?
6JH volatility
6JH Average Weekly Movement	n/a
Biotechs Industry Average Movement	5.3%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.6%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: 6JH heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van 6JH in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2016	26	Will Ho	in8bio.com

IN8bio, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van IN8bio zich tot de beurswaarde?
6JH fundamentele statistieken
Marktkapitalisatie	€35.54m
Inkomsten(TTM)	-€25.70m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-1.4x

Koers/Winstverhouding

Is 6JH overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
6JH resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$26.57m
Inkomsten	-US$26.57m

Laatst gerapporteerde inkomsten

Sep 30, 2022

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.08
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde 6JH op de lange termijn?

Bekijk historische prestaties en vergelijking

6JH Overzicht aandelen

Beloningen

Risicoanalyse

IN8bio, Inc. Concurrenten

XTRA:MDG1

€25.0m

XTRA:2INV

€59.8m

DB:VSC

€61.5m

XTRA:HPHA

€111.9m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

IN8bio, Inc. announced that it expects to receive $12.405547 million in funding

IN8bio, Inc. Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia

IN8bio, Inc. Announces Updated Positive Clinical Data from Both of the Phase 1 Investigator-Sponsored Trials of INB-100 for Hematological Malignancies and INB-200 for GBM

IN8bio, Inc. Presents Positive Data Demonstrating Durable 1-Year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100

IN8bio, Inc. Presents Progression-Free Survival Update from Phase 1 Study of INB-200 At 2024 American Society of Clinical Oncology Annual Meeting

In8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation At Asgct 2024

Recent updates

IN8bio, Inc. announced that it expects to receive $12.405547 million in funding

IN8bio, Inc. Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia

IN8bio, Inc. Announces Updated Positive Clinical Data from Both of the Phase 1 Investigator-Sponsored Trials of INB-100 for Hematological Malignancies and INB-200 for GBM

IN8bio, Inc. Presents Positive Data Demonstrating Durable 1-Year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100

IN8bio, Inc. Presents Progression-Free Survival Update from Phase 1 Study of INB-200 At 2024 American Society of Clinical Oncology Annual Meeting

In8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation At Asgct 2024

In8bio, Inc. Doses First Patient in Phase 2 Clinical Trial of Inb-400 in Newly Diagnosed Glioblastoma

IN8bio, Inc., Annual General Meeting, Jun 12, 2024

IN8bio, Inc. Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024

IN8bio, Inc. to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024

IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology

IN8bio, Inc. announced that it has received $14.442298 million in funding from Bios Equity Partners LP

IN8bio, Inc. announced that it expects to receive $14.442298 million in funding

IN8bio, Inc. Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia

IN8bio, Inc. Appoints Corinne Epperly to the Board of Directors

IN8bio, Inc.’s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma

IN8bio, Inc. Presents Biologic Correlative Data from the Inb-200 Phase 1 Trial in Newly Diagnosed Glioblastoma At the Society for Immunotherapy of Cancer's 38Th Annual Meeting

IN8bio, Inc. Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma

IN8bio, Inc. Announces Presentations at the Society for Immunology of Cancer 38th Annual Meeting

IN8bio, Inc. Announces Updated Data from the Ongoing Phase 1 Clinical Trial of Inb-200 in Patients with Newly Diagnosed Glioblastoma Multiforme

IN8bio, Inc. Announces Positive Preclinical Data Underscoring the Potential of Its DeltEx Gamma-Delta T Cells to Target and Kill Ovarian Cancer

IN8bio Provides INB-200 Clinical Update and Outlines 2023 Pipeline Goals

In8bio Announces New Data At Ash Showing 100% of Cohort 1 Patients Maintained Durable Complete Response in Ongoing Phase 1 Trial of Inb-100

IN8bio Announces FDA Clearance to Initiate A Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma

IN8bio to Present Positive Early Data from Ongoing Phase 1 Study of INB-100 at the 64th American Society of Hematology Annual Meeting

IN8bio, Inc. Appoints Michael R. Bishop to Its Scientific Advisory Board

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

IN8bio, Inc. Samenvatting

0.0x

-1.4x

Inkomsten en omzet